Jeena Sikho Lifecare Limited (JSLL), a leading Ayurvedic healthcare service provider, has announced robust financial results for the second quarter, demonstrating significant growth across key metrics.

Financial Highlights

The company reported a 66% year-on-year increase in revenue for Q2, reaching ₹189.85 crore, up from ₹114.09 crore in the same quarter last year. This growth was accompanied by a 9% sequential increase from Q1.

JSLL's profitability also saw substantial improvement:

Operational Performance

The company's growth was driven by strong patient volume expansion:

• IPD (In-Patient Department) volumes increased by 57% YoY to 9,614 patients
• OPD (Out-Patient Department) volumes grew by 67% YoY to 1.40 lakh patients
• Day Care volumes surged by 169% YoY to 17,154 patients

Capacity Expansion

Jeena Sikho Lifecare continued its expansion initiatives:

• Three new hospitals became operational during the quarter
• Total operational bed capacity increased to over 2,220 beds
• Approximately 400 additional beds are under development across five facilities

Strategic Focus

The company is increasingly focusing on the private business segment, which offers superior margins compared to the Government Panel segment. This shift in business mix is expected to further strengthen profitability and improve the overall cash-conversion cycle.

Product Development

JSLL's OTC and Medicines division continues to perform strongly, supported by the launch of new products such as Dr. BP Care DS, Dr. Kidney Care DS, Dr. Madhu Care DS, Dr. Liver DS, and Dr. Sukoon DS. The company plans to launch six additional products in the remainder of the year.

Technology Partnership

Jeena Sikho Lifecare has entered into a strategic partnership with Salesforce to strengthen its technology infrastructure and operational workflows. This collaboration aims to enhance operational efficiency, optimize patient engagement, and broaden access to holistic healthcare across digital platforms.

Management Commentary

Acharya Manish Ji, Managing Director of Jeena Sikho Lifecare, commented on the results: "Our strong performance in Q2 underscores the resilience of our business model and the effectiveness of our strategic initiatives. We remain committed to delivering consistent growth and long-term value for all stakeholders through our ongoing capacity expansion, operational excellence measures, and differentiated product portfolio."

Jeena Sikho Lifecare Limited (JSLL), a leading Ayurvedic healthcare provider, has reported robust financial results for the second quarter, showcasing significant growth across key metrics.

Financial Highlights

JSLL delivered impressive quarterly results, with net profit soaring to ₹588.00 million from ₹266.00 million year-over-year, marking a substantial 121% increase. The company's revenue grew significantly to ₹1,898.50 million, up from ₹1,140.90 million in the same period last year, representing a 67% growth.

Operational Performance

The company's EBITDA more than doubled to ₹920.60 million from ₹402.70 million year-over-year. Notably, JSLL's EBITDA margin expanded substantially to 48.49% from 35.30% in the previous year, indicating improved operational efficiency and profitability.

Key Performance Indicators

Operational Expansion

JSLL continues to expand its operational footprint. The company reported that three new hospitals became operational during the quarter, increasing the total operational bed capacity to over 2,220 beds. Additionally, approximately 400 beds are currently under development across five facilities.

Strategic Focus

The company has been strategically shifting its focus towards the private business segment, which offers superior margins compared to the Government Panel segment. This shift in business mix is expected to further strengthen profitability and improve the overall cash-conversion cycle.

Product Portfolio Expansion

JSLL's OTC and Medicines division continues to deliver strong performance, supported by the launch of new products such as Dr. BP Care DS, Dr. Kidney Care DS, Dr. Madhu Care DS, Dr. Liver DS, and Dr. Sukoon DS. These products have been well-received in the market, driving consistent growth in product revenues.

Technology Integration

JSLL has entered into a strategic partnership with Salesforce, a globally recognized leader in cloud-based enterprise solutions. This collaboration is expected to significantly elevate the quality of patient care and operational efficiency.

Management Commentary

Acharya Manish Ji, Managing Director of JSLL, commented on the results, stating, "Jeena Sikho continued to maintain strong business momentum during the first half of the financial year. Our strategic initiatives and consistent operational excellence have resulted in robust growth for H1 FY26 compared to the previous financial year."

He further added, "Our expansion initiatives remained on track during the quarter, and the enhanced utilization of existing capacity has further improved operational efficiency and contributed positively to margin expansion."

The company's strong performance and strategic initiatives position it well for continued growth in the Ayurvedic healthcare sector.